Charu Jain, Anurag Makkar, V.K. Malik


Introduction-Conjunctivitis is the most common eye disease worldwide. As the treatment of vernal keratoconjunctivitis is still a dilemma,  there is a need for devising a treatment modality that is safe as well as effective in refractory vernal keratoconjunctivitis (VKC).

Aim- To study the efficacy and safety profile of 0.03% tacrolimus eye ointment in refractory vernal keratoconjunctivitis.

 Material &methods-70 eyes of 35 patients with refractory VKC were included in the study. 0.03% tacrolimus eye ointment was given two times a day and patients were followed up at 1st,3rd,6th and 12th week .

Results- At the end of 12 weeks there was a  marked reduction in the mean score of symptoms and signs  (p<0.001). The drug was well tolerated and no complication was reported in any patient.

Conclusion-0.03% tacrolimus ointment is safe and  effective in  treatment of refractory vernal keratoconjunctivitis   VKC.


Refractory,Vernal keratoconjunctivitis (VKC), Tacrolimus

Full Text:



Attas Fox, Barkana Y, Rayvich S et al. Evaluate the effectivity of dermatological 0.03% tacrolimus ointment (protopic) in the treatment of intractable allergic conjunctivitis. Curr Eye Res 2008; 33(7): 545-49.

Bieolory L, Frohman LP. Allergic and immunologic disorders of the eye. J Allergy Clin Immunol 1992; 89(1): 1-15.

Hazarika AK, Singh PK. Efficacy of topical application of 0.03% tacrolimus eye ointment in the management of allergic conjunctivitis. J Nat Sci Bio Med. 2015; 6(1):10-12.

Hooks MA. Tacrolimus a new immunosuppresent: a review of the literature. Ann Pharmacother 1994; 28: 501-11.

Iwamoto H, Yoshida H, Yoshida O et al. Inhibitory effects of FK-506 on the development of experimental allergic/immune mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration. Graefes Arch Clin Exp Ophthalmol 1999; 237(5): 407-14.

Jones BR. Vernal Keratitis. Trans Ophthalmol Soc UK 1961;81(2):5-28.

Kheirkhah A, Zavereh MK, Farzbod F et al. Evaluate the efficacy and safety of topical 0.005% tacrolimus eye drop for treatment of refractory vernal keratoconjunctivitis. Eye 2011;25:872-80.

Kino T, Hatanaks H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from a streptomyces.1. Fermentation, isolation and physio-chemical and biological characteristics. J Antibiot 1987; 40: 1249-55.

Kymionis GD, Goldman D, Ide T et al. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea 2008; 27 (2): 228-29.

Mochizuki M, Ikeda E, Shirao M et al. Preclinical and clinical study of FK-506 in uveitis. Curr Eye Res 1992; 11(Suppl): 87-95.

Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK-506. Immunol Today. 1992; 13: 136-42.

Secchi AG, Tongon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990; 110(6): 641-45.

Shoughy SS, Jaroudi MO, Tabbara KF. Efficacy and safety of low dose topical tacrolimus in vernal keratoconjunctivitis. Clin Ophthalmol 2016;7(10):643-47.

Tabbara KF. Occular complications of Vernal Keratoconjunctivitis. Can J Ophthalmol 1999; 34(2): 88-92.

Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P et al. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol 2004; 113(2): 355-58.

Yalcindag FN, Incel O, Ozdemir O. Effectiveness of tacrolimus in high risk limbal allo-graft transplantation. Ann Ophthalmol 2008; 40(3-4): 152-56.

Zribi H, Descamps V, Hoang-Xuan T, Crickx B, Doan S. Dramatic improvement of atopic keratoconjunctivitis after topical treatment with tacrolimus ointment restricted to the eyelids. J Eur Acad Dermatol Venereol 2009; 23(4): 489-90.


  • There are currently no refbacks.